- Human（1）
- Mouse（1）
No data
- Tag Free（2）
No data
- HEK293（2）
No data
- Unconjugated（2）
No data
- PG (pre-GMP)（1）
- RUO（1）
No data
- Yes（1）
- No（1）
No data
- 20ug/$90.00
- 50ug/$135.00
- 500ug (250ug X 2)/$805.00
No data
- 20ug/$90.00
- 50ug/$135.00
- 500ug/$805.00
No data
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Beta-NGF | Human Beta-NGF Protein, premium grade |  Human | HEK293 |  | MALSSDS-PAGE | $90.00 20ug |   | ||
| Beta-NGF | Mouse Beta-NGF Protein, Tag Free, low endotoxin (MALS verified) |  Mouse | HEK293 |  | MALSSDS-PAGE | $90.00 20ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| RGN-259 | RGN-457; RGN-352; RGN-259; RGN-137; Tβ4; TB4; GBT-101; GBT-201; Thymosin beta 4-16-38; TB4 16-38; Thymosin beta4; Thymosin B4; Fx peptide | Phase 3 Clinical | National Institutes Of Health | Diabetes Mellitus; Dry Eye Syndromes; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Graft vs Host Disease; Keratitis; Myocardial Infarction; Myocardial Ischemia; Pressure Ulcer; Sjogren's Syndrome; ST Elevation Myocardial Infarction; Varicose Ulcer; Xerophthalmia | Details |
| Fasinumab | SAR-164877; MT-5547; R-475; REGN-475 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Abdominal Pain; Back Pain; Low Back Pain; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Sciatica | Details |
| SSS-40 | SSS-40; SSS-40-anti-NGF Ab; SSS40 anti-NGF Ab | Phase 2 Clinical | 3sbio Inc | Bone Neoplasms; Cancer Pain; Osteoarthritis | Details |
| SHR-2017 | SHR-2017; SHR2017 | Phase 2 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Bone metastases; Multiple Myeloma; Osteoporosis; Solid tumours | Details |
| Antibodies to humanized nerve growth factor(Shenyang Sunshine Pharmaceutical) | Phase 2 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Bone metastases; Cancer Pain | Details | |
| EP-9001A | EP-9001A | Phase 2 Clinical | Chengdu Youluo Biotechnology Co Ltd | Bone metastases; Cancer Pain; Pain | Details |
| DS-002 | DS-002 | Phase 2 Clinical | Dartsbio Pharmaceuticals Ltd | Cancer Pain; Pain | Details |
| Atinumab | NG-101; ATI-355 | Phase 2 Clinical | Novartis Pharma Ag | Diabetic Gastroparesis; Gastroparesis; Spinal Cord Injuries | Details |
| Luvagrobart | AK-115 | Phase 1 Clinical | Cancer Pain; Pain | Details | |
| 4B03-04 | 4B03-04 | Phase 1 Clinical | Fubei Biomedical Technology (Beijing) Co Ltd | Osteoarthritis | Details |
| DS-010 | DS010; DS-010 | Phase 1 Clinical | Dartsbio Pharmaceuticals Ltd | Cachexia | Details |
| TNM-009 | TNM-009; TNM009 | Phase 1 Clinical | Zhuhai Trinomab Pharmaceutical Co Ltd | Cancer Pain; Pain | Details |
| SMR-7694 | SMR-7694; SMR7694 | Phase 1 Clinical | Sinobioway Biomedicine Co Ltd | Osteoarthritis | Details |
| Neuroregenerative agents (iNtRON Biotechnology) | Clinical | Intron Biotechnology | Nervous System Diseases | Details |
